Arnau Montraveta
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
Journal: British journal of haematology
Published: August 25, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 19, 2016
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Journal: Oncotarget
Published: September 22, 2015
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Journal: Oncotarget
Published: May 15, 2015
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Journal: Oncotarget
Published: March 23, 2015
Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.
Journal: The pharmacogenomics journal
Published: June 18, 2014
Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Journal: Oncotarget
Published: February 13, 2014
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Journal: Leukemia
Published: January 02, 2014
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
Journal: Leukemia
Published: November 20, 2013
Last Updated: 09/26/2026